Last reviewed · How we verify
Placebo semaglutide
Placebo semaglutide is an inactive formulation containing no active pharmaceutical ingredient and produces no pharmacological effect.
Placebo semaglutide is an inactive formulation containing no active pharmaceutical ingredient and produces no pharmacological effect. Used for Clinical trial control comparator (not a therapeutic indication).
At a glance
| Generic name | Placebo semaglutide |
|---|---|
| Also known as | Rybelsus, Placebo semaglutide, Rybelsus tablet |
| Sponsor | Novo Nordisk A/S |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo semaglutide is used as a control comparator in clinical trials. It contains no semaglutide or other active agent and serves to establish the baseline effect of treatment expectation and study procedures, allowing researchers to isolate the true pharmacological effects of active semaglutide through comparison.
Approved indications
- Clinical trial control comparator (not a therapeutic indication)
Common side effects
Key clinical trials
- A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) (PHASE3)
- Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss (PHASE2)
- Repurposing Semaglutide for the Treatment of Cocaine Use Disorder (PHASE2)
- Probiotic Intervention on Body Weight (NA)
- Protein Supplementation Intervention on Body Weight (NA)
- GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV (PHASE2)
- Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes (PHASE3)
- Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo semaglutide CI brief — competitive landscape report
- Placebo semaglutide updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI